Priapismo secundario a tratamiento por cabergolina: primera descripción de esta asociación

Zarzuelo, E. De la Peña; Cañas, V. Hernández; Abarca, C. Llorente

doi:10.1016/j.acuro.2009.11.011

Search citation statements

Order By: Relevance

Paper Sections

Select...

Discussion1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2012

2021

Publication Types

Select...

Article5

Book1

Relationship

Self Cite0

Independent6

Authors

Journals

Cited by 6 publications

(1 citation statement)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Priapism due to cabergoline therapy for prolactinoma was first reported in 2010. 9 A subsequent report notes the occurrence of priapism 60 days after the initiation of cabergoline. 10 Priapism has also been reported with the use of transdermal rotigotine, a nonselective dopamine agonist, at a dose of 4 mg per 24 hours for the treatment of Parkinson’s disease.…”

Section: Discussionmentioning

confidence: 99%

Recurrent Priapism From Cabergoline and Bromocriptine in a Hypogonadal Man With Prolactinoma

Menon

Rahman

2021

Journal of Investigative Medicine High Impact Case Reports

View full text Add to dashboard Cite

Dopamine agonists are generally well tolerated and represent the first-line therapy for prolactinomas. We report a case of a 20-year-old man with a macroprolactinoma who developed recurrent priapism with cabergoline and bromocriptine. Transsphenoidal pituitary adenoma resection was done with normalization of the prolactin level. Priapism is a rare side effect of dopamine agonists that warrants discontinuation of therapy. Patients should be educated about this potential side effect at the time of prescribing the medication.

show abstract

Section: Discussionmentioning

confidence: 99%